Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417162 | 0.82 | SMN1; SMN2 (0.43) | PKMALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL4411990 | 0.82 | ALDH1A1 (0.47) | PKMALDH1A1SMN1; SMN2MAPK1FKBP1A | |
| SCHEMBL4422235 | 0.82 | KDM4E (0.48) | ALDH1A1SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL4412007 | 0.81 | MAPT (0.46) | CA1CA2CA9CA14FKBP1A | |
| SCHEMBL4414625 | 0.81 | CA1 (0.45) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL13972868 | 0.81 | CA1 (0.41) | CA1CA2CA9CA14FKBP1A | |
| SCHEMBL4412933 | 0.81 | CA1 (0.41) | CA1CA2CA9CA14FKBP1A | |
| SCHEMBL4414620 | 0.78 | FKBP1A (0.44) | ALDH1A1CA1CA2CA9CA14 | |
| SCHEMBL6505778 | 0.78 | HTR6 (0.44) | CA1CA2CA9CA14GRIN2C | |
| SCHEMBL4412965 | 0.78 | HCRTR1 (0.44) | PKMALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | PKM 1619/4885ALDH1A1 3171/4885SMN1; SMN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.